Corcept Therapeutics Director James N. Wilson Sells $1.15M in Common Stock Under Rule 10b5-1 Plan
CORCEPT THERAPEUTICS INC
Subscribe to track CORT
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Sale Alert: Corcept Therapeutics Inc ($CORT)
**Insider:** James N. Wilson (Director)
**Transaction Date:** 2026-10-15
**Type:** Sale (Open Market, Rule 10b5-1 Plan)
**Shares Sold:** 10,000
**Average Price:** $114.81
**Total Value:** ~$1,148,083
**Shares Remaining:** 1,454,543 (across family trusts)
*Note: Executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.*
Comprehensive Analysis
Executive Summary
On October 15, 2026, Corcept Therapeutics Inc ($CORT) Director James N. Wilson sold a total of 10,000 shares of common stock indirectly held through the James N. Wilson and Pamela D. Wilson Trust. The transactions were executed at weighted average prices ranging from $114.48 to $116.30, generating approximately $1.15 million in gross proceeds.
Transaction Breakdown
- Tranche 1: 6,654 shares sold at a weighted average price of $114.4751 (range: $114.13 - $115.12)
- Tranche 2: 3,046 shares sold at a weighted average price of $115.3895 (range: $115.16 - $116.10)
- Tranche 3: 300 shares sold at a weighted average price of $116.2967 (range: $116.19 - $116.35)
- Aggregate Volume: 10,000 shares
- Blended Average Price: ~$114.81 per share
Context and Holdings
- 10b5-1 Plan Execution: The sales were executed under a pre-established Rule 10b5-1 trading arrangement adopted on March 12, 2026.
- Remaining Holdings: Following the transaction, the James N. Wilson and Pamela D. Wilson Trust maintains 1,054,543 shares. In addition, Mr. Wilson reports 200,000 shares held in the James N. Wilson 2025 GRAT and 200,000 shares held in the Pamela D. Wilson 2025 GRAT, bringing total indirect holdings to 1,454,543 shares.
- Proportionality: The sale of 10,000 shares represents less than 1% of Mr. Wilson's total reported indirect equity stake.
Market Significance
The transaction carries Low market significance due to its execution under a pre-arranged 10b5-1 trading plan and the minimal reduction in Mr. Wilson's overarching beneficial ownership.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.